LSL Pharma Group Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Jun '26 Jun 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '22 Jul 31, 2022
Market Cap	40	41	43	40	-	-
Market Cap Growth	-12.34%	-4.75%	8.10%	-	-	-
Enterprise Value	61.61	77.41	62.89	50.91	0	0
Last Close Price	0.33	0.35	0.41	0.49	-	-
PE Ratio	14.54	-	13.67	-	-	-
PS Ratio	1.49	1.43	2.44	3.99	-	-
PB Ratio	1.58	1.53	1.74	4.62	-	-
P/TBV Ratio	2.50	1.53	1.74	4.51	-	-
EV/Sales Ratio	2.30	2.69	3.54	5.08	-	-
EV/EBITDA Ratio	15.36	193.04	26.96	-	-	-
EV/EBIT Ratio	43.54	-	76.32	-	-	-
Debt / Equity Ratio	1.70	1.36	0.80	1.26	2.68	-
Debt / EBITDA Ratio	-	95.64	9.37	-	-	-
Net Debt / Equity Ratio	1.78	1.40	0.87	1.88	3.00	-
Net Debt / EBITDA Ratio	-28.20	94.27	9.24	-18.69	-1.23	-
Net Debt / FCF Ratio	-5.81	-8.47	-4.52	-2.10	-3.82	-
Asset Turnover	0.44	0.45	0.42	0.34	0.60	0
Inventory Turnover	2.07	2.19	1.86	2.37	7.02	-
Quick Ratio	0.38	0.59	0.54	0.18	0.11	-
Current Ratio	1.33	2.34	1.59	0.48	0.38	-
Return on Equity (ROE)	-23.95%	-10.87%	19.78%	-121.50%	-315.83%	0.00%
Return on Assets (ROA)	-5.68%	-3.24%	1.92%	-6.87%	-102.01%	0.00%
Return on Invested Capital (ROIC)	-6.36%	-3.59%	2.01%	-6.53%	-97.73%	0.00%
Return on Capital Employed (ROCE)	-7.05%	-3.93%	2.76%	-12.68%	-179.76%	0.00%
Earnings Yield	6.94%	-	7.32%	-	-	-
Buyback Yield / Dilution	-19.11%	-11.58%	-31.13%	-19.66%	-	-
Total Shareholder Return	-19.11%	-11.58%	-31.13%	-19.66%	-	-